|Day Low/High||112.66 / 113.29|
|52 Wk Low/High||91.53 / 125.20|
Regeneron has faced a lower stock price and patent wrangling. But the stock could be ready to rise again.
U.S. stock futures and shares in London and Asia fall Thursday after Donald Trump offers few details on his policies during his first press conference since winning the U.S. election.
European health care and pharmaceutical company shares were hit hard Thursday after President-elect Donald Trump accused some firms of 'getting away with murder' in his Wednesday press conference.
Elizabeth Lim, Mergermarket America head research editor, expects further energy consolidation and increased media mergers in 2017.
While there is deep uncertainty about how politics will affect the health care sector in the new year, analysts seem excited about some opportunities in pharmaceuticals.
European stocks opened a holiday-thinned session with caution as U.S. dollar strength continues to drive sentiment.
U.K. stocks are buoyed by retail sales at a 14-year high, prompting a resurgence of consumer and real estate stocks.
European stocks are in the red Wednesday as government bond yields edge higher amid the global inflation trade.
A sale or spinoff of this business will likely get the attention of competitors that want to increase their over-the-counter product units.
Pfizer, Bayer, Shire are among rivals bracing for Roche's ACE910.
A WWF report shows how fragile our hold on the world's ecology is. Does Asia represent the future of food production?
Some of the biggest deals already announced on Wall Street are currently pricing in hefty premiums for investors willing to take the risk.
Strong drug sales allow the German group to increase its full-year earnings forecast, while wilting crop science revenue pose more questions about the wisdom of buying Monsanto.
U.K. lender Lloyds falls after a third-quarter profit miss, while luxury goods maker Kering surges.
This is new doctrine having to do with innovation and the stifling of innovation to create new products.
The Swiss fertilizers maker says regulators in the EU and elsewhere have demanded more information.
Results have shown that many major "blockbuster" deals aren't blockbuster investments later.
Regulatory issues will weigh on this deal, because of populist politics.
Forward-looking purchasing managers' indices and earnings from beleaguered lender Deutsche Bank feature among the other release highlights.
Here is why CBS, Constellation Brands, Monsanto and Aetna will be winners in 2017.
Experts say mutual funds' stakes across an industry can thwart competition and that anti-trust regulators should require them to pare their holdings in that case.
Buy mutual funds and exchange-traded funds that buy shares of those companies involved in takeovers.
Conditions seem ripe for continued upward momentum in stocks, as long as the Federal Reserve or unexpected shocks don't get in the way.
CEO Werner Baumann increases sales and margin forecasts for pharmaceuticals and insists Monsanto deal will deliver growth and improved profit.
Despite intense opposition from farm groups and skepticism from government enforcers, the merging crop technology giants say they expect to win approval by end of 2017.
Another selloff on commodity markets on Wednesday contributed to stock losses throughout the day.
Stocks lose highs by mid-afternoon Wednesday as a selloff in crude resumes.